C WorldWide Group Holding A S Lowers Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

C WorldWide Group Holding A S reduced its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 23.5% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 71,557 shares of the pharmaceutical company’s stock after selling 22,000 shares during the period. Vertex Pharmaceuticals makes up 0.4% of C WorldWide Group Holding A S’s investment portfolio, making the stock its 27th biggest position. C WorldWide Group Holding A S’s holdings in Vertex Pharmaceuticals were worth $29,116,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in the company. Sherbrooke Park Advisers LLC raised its holdings in shares of Vertex Pharmaceuticals by 65.3% during the 3rd quarter. Sherbrooke Park Advisers LLC now owns 2,645 shares of the pharmaceutical company’s stock valued at $920,000 after buying an additional 1,045 shares in the last quarter. Robeco Institutional Asset Management B.V. raised its stake in shares of Vertex Pharmaceuticals by 6.5% during the third quarter. Robeco Institutional Asset Management B.V. now owns 432,937 shares of the pharmaceutical company’s stock worth $150,550,000 after acquiring an additional 26,523 shares in the last quarter. Telos Capital Management Inc. lifted its holdings in shares of Vertex Pharmaceuticals by 1.6% in the 4th quarter. Telos Capital Management Inc. now owns 15,073 shares of the pharmaceutical company’s stock worth $6,133,000 after acquiring an additional 237 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Vertex Pharmaceuticals by 1.3% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 427,001 shares of the pharmaceutical company’s stock valued at $148,485,000 after purchasing an additional 5,514 shares in the last quarter. Finally, Machina Capital S.A.S. bought a new position in shares of Vertex Pharmaceuticals during the 3rd quarter valued at $816,000. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Trading Down 0.1 %

VRTX traded down $0.22 during trading on Friday, reaching $397.48. The company had a trading volume of 682,467 shares, compared to its average volume of 909,553. The company has a quick ratio of 3.78, a current ratio of 3.99 and a debt-to-equity ratio of 0.02. The business has a 50 day simple moving average of $411.60 and a 200-day simple moving average of $398.67. The stock has a market cap of $102.73 billion, a P/E ratio of 28.62, a PEG ratio of 1.87 and a beta of 0.35. Vertex Pharmaceuticals Incorporated has a 52 week low of $320.01 and a 52 week high of $448.40.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share for the quarter, topping the consensus estimate of $3.85 by $0.35. The firm had revenue of $2.52 billion for the quarter, compared to the consensus estimate of $2.50 billion. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. During the same period in the previous year, the business earned $3.33 EPS. On average, equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 14.95 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Ourania Tatsis sold 354 shares of the company’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $425.70, for a total value of $150,697.80. Following the transaction, the executive vice president now directly owns 55,804 shares of the company’s stock, valued at approximately $23,755,762.80. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, CAO Kristen Ambrose sold 1,374 shares of the business’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $420.24, for a total value of $577,409.76. Following the completion of the transaction, the chief accounting officer now owns 9,676 shares of the company’s stock, valued at approximately $4,066,242.24. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Ourania Tatsis sold 354 shares of the firm’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $425.70, for a total value of $150,697.80. Following the sale, the executive vice president now directly owns 55,804 shares in the company, valued at $23,755,762.80. The disclosure for this sale can be found here. In the last quarter, insiders have sold 12,381 shares of company stock valued at $5,203,249. Insiders own 0.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Truist Financial boosted their price objective on shares of Vertex Pharmaceuticals from $456.00 to $508.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. Guggenheim upped their price target on shares of Vertex Pharmaceuticals from $445.00 to $450.00 and gave the company a “buy” rating in a research report on Thursday, April 18th. UBS Group decreased their price objective on Vertex Pharmaceuticals from $498.00 to $466.00 and set a “buy” rating on the stock in a research note on Wednesday, April 17th. Sanford C. Bernstein downgraded Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Friday, February 2nd. Finally, Robert W. Baird cut shares of Vertex Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $325.00 target price on the stock. in a research note on Wednesday, January 31st. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $429.45.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.